Scientists have found a gene variant that helps explain why some people shed more weight than others on drugs like Ozempic and Wegovy.
Quick Take
- A new study of nearly 28,000 people linked a gene called GLP1R to extra weight loss on GLP-1 drugs
- People with one copy of the variant lost about 0.76 kilograms more on average; two copies meant roughly 1.5 kilograms more
- The same study tied gene differences to nausea and vomiting, with one side-effect link showing up only in tirzepatide users
- Researchers used self-reported data from 23andMe customers, not controlled clinical trial records
What The Study Actually Found
Researchers published the findings in Nature after studying 27,885 people who reported taking GLP-1 receptor agonist drugs. They zeroed in on a gene variant called rs10305420, found in the GLP1R gene. People carrying this variant tended to lose noticeably more weight than those without it, and the statistical link was strong, with odds of it being a fluke calculated at about one in several billion.
The effect grew with each copy of the gene a person carried. One copy added about 0.76 kilograms of extra weight loss over a median of eight months. Two copies nearly doubled that bonus, to roughly 1.5 kilograms. That is a real, measurable pattern, but it is a modest slice of the total weight most people lose on these drugs, not a guarantee of how any one patient will respond.
Side Effects Have A Genetic Fingerprint Too
The study did not stop at weight loss. Researchers also found links between gene variants and unpleasant side effects like nausea and vomiting. One variant, in a gene called GIPR, showed this connection specifically among people taking tirzepatide, the active ingredient in Mounjaro and Zepbound. That detail matters because it means the finding cannot be stretched to cover every GLP-1 drug on the market.
Semaglutide, sold as Ozempic and Wegovy, works on a different biological pathway than tirzepatide, which acts on two separate hormone receptors. Lumping every GLP-1 medication into one bucket when discussing side-effect genetics risks overstating what the data actually shows. The nausea-and-vomiting link tied to GIPR belongs to tirzepatide users in this dataset, not the whole drug class.
Why This Fits A Pattern Doctors Already Know
Doctors have long known that GLP-1 drugs do not work the same for everyone. Some patients lose twenty percent of their body weight. Others lose very little or quit because their stomach cannot handle it. Earlier research pointed to differences in baseline weight, blood sugar status, sex, appetite biology, and simple adherence to the prescribed dose as drivers of that gap. Genetics now joins that list as one more piece, not a replacement for the others.
Earlier, smaller studies had already flagged GLP1R variants as possibly influencing how patients respond to older diabetes drugs like liraglutide and exenatide. Those findings were inconsistent from study to study. The new Nature study is far larger, giving its results more statistical weight, but it still sits inside a research tradition that has struggled to produce one clean, repeatable answer about genetics and GLP-1 response.
The Data Came From A Consumer Genetics Company, Not A Hospital
The participants were customers of 23andMe, the direct-to-consumer genetic testing company, who voluntarily reported using GLP-1 drugs and shared their own weight-loss and side-effect experiences. That is a massive sample size for genetics research, but it relies on people accurately remembering and reporting their own outcomes rather than clinic-measured weight or medically verified adverse events.
What Comes Next For Patients And Doctors
Scientists say the logical next step is testing this same gene variant inside actual clinical trials, where dosing, adherence, and weight are tracked by medical staff instead of self-report. Researchers also want to know whether combining several genetic markers into one score could someday help doctors predict, before a prescription is even written, who will respond well and who might struggle with side effects.
For now, patients should not expect a genetic test to tell them whether Ozempic or Mounjaro will work for their body. The variant explains a sliver of the picture. Diet, dose, consistency, and basic biology still carry far more weight than any single gene. Genetics may eventually sharpen how doctors prescribe these drugs, but that future is not here yet.
What is clear today is that the one-size-fits-all approach to GLP-1 prescribing is being questioned by real data, not guesswork. That is a reasonable, common-sense direction for medicine to move, provided researchers keep testing these claims in bigger, more rigorous studies before doctors start making decisions based on a single gene.
Sources:
reuters.com, nature.com, ddnews.gov.in, thepathologist.com
